Incannex Healthcare Inc. 8K

Incannex Healthcare Inc. received a granted U.S. patent providing long-term protection for its IHL-42X obstructive sleep apnoea therapy, enhancing the asset’s commercial and strategic value as it progresses in clinical development.

On June 25, 2026, Incannex Healthcare Inc. announced that the United States Patent and Trademark Office granted a key U.S. patent titled “Compositions and Methods of Treatment for Obstructive Sleep Apnea” covering the proprietary composition and therapeutic use of its lead candidate IHL-42X for obstructive sleep apnoea, with a baseline expiry of July 9, 2040 and potential for patent term extension, thereby materially strengthening the company’s intellectual property position and long‑term market exclusivity for this program while it advances IHL-42X through its DReAMzz Phase 2 dose-optimization study toward Phase III development.

Filing Facts

CIK

1873875

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-071745

Alert Tier

6